Trials & Filings

Endocyte To Continue NSCLC Study

Vintafolide not likely to be superior to docetaxel as monotherapy

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Endocyte will continue its non-small cell lung cancer (NSCLC) trial of vintafolide after an independent Data Safety Monitoring Board (DSMB) review of the interim futility analysis for the Phase IIb trial. The DSM recommended the continuation of two arms of the trial, vintafolide combination therapy (investigational) and docetaxel monotherapy (control), but recommended that investigators and patients be advised that vintafolide monotherapy is not likely to be declared superior to docetaxel in pro...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters